nivolumab,ipilimumab
bms
['lung', 'nivolumab', 'ipilimumab', 'nivo', 'lcsm,(-blcsm)', 'sclc']
research shared by #asco23 demonstrates clinical activity using ipilimumab/nivolumab, a dual checkpoint inhibitor blockade, in patients with small cell lung cancer #sclc #lcsm 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.